Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera

Shots:

• Ionis has granted Ono Pharma an exclusive global license to develop & commercialize sapablursen for the treatment of polycythemia vera (PV)
• As per the deal, Ionis will get $280M upfront & ~$660M in development, regulatory & sales milestones, plus mid-teens net sales-based royalties as well as Ionis will be responsible to complete ongoing P-II (IMPRSSION) study, while Ono handles further development, regulatory filings & marketing
• Sapablursen reduces TMPRSS6 production, which increases hepcidin levels responsible for iron homeostasis to provide therapeutic relief in blood diseases like PV

Ref: Businesswire | Image: Ono Pharma & Ionis

Related News:- Ono Pharmaceutical Reports the US FDA Approval of Romvimza to Treat Symptomatic Tenosynovial Giant Cell Tumor (TGCT) in Adults

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com